Prognostic value of determining serum CA125 and IL-10 levels in patients with advanced non-mall cell lung cancer

Li XU,Ye-han ZHU
DOI: https://doi.org/10.3969/j.issn.1009-6663.2016.04.010
2016-01-01
Abstract:Objective To explore prognostic value to determine serum CA125 and IL-10 in patients with non-small cell lung cancer(NSCLC). Methods The serum CA125 and IL-10 levels were determined in 132 pa-tients with advanced NSCLC before and after chemo and radio therapy, and 76 patents with benign lung disease were taken as the control group. The receiver operating characteristic(ROC)curve was plotted to analyze CA125 and IL-10 as a prognostic clinical value indicator of survival. Results The serum CA125 and IL-10 levels in the study group(including 51 cases of lung adenocarcinoma, 53 cases of lung squanous carcinoma and 28 cases of adeno-squanous carcinoma)were significantly higher than those in the control group(P<0. 05~0. 001). The disease counts of ser-um CA125 and IL-10 levels in patients with Ⅳ stages and low differentiated NSCLC were significantly higher than those in patients with Ⅲa stages and high differentiated(P<0. 05). The serum CA125 and IL-10 levels decreased obviously in 47 PR patients after therapy, and significantly longer than those in 37 patients with PD(P all<0. 05). ROC curve analysis showed that the AUC were 0. 803 and 0. 764 respectively, and the cut-off points were 84. 1U/ml and 65. 2ng/L, respectively. The sensitivity were 81. 5% and 77. 4% respectively, and the specificity were 87. 6%and 80. 1% for CA125 and IL-10 as a prognostic clinical value indicator. Conclusion The serum CA125 and IL-10 can be used as independent prognostic parameters in advanced NSCLC.
What problem does this paper attempt to address?